echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Many pharmaceutical companies rushed into the fifth batch of national procurement

    Many pharmaceutical companies rushed into the fifth batch of national procurement

    • Last Update: 2021-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    With the approach of the fifth batch of national procurement bids, more and more companies have obtained tickets for the national procurement bidding


    1.


    1.


    According to the Insight database, Shanghai Shangyao Xinya's Lansoprazole for injection is the 5th company that has been evaluated


    Hainan Beite’s azithromycin injection passed the consistency evaluation on March 22, and this time it is the new specification


    Hanyu Pharmaceutical's Thymus Law is the fifth company to pass the consistency evaluation, and two other companies are in the process of applying for supplementary consistency evaluation


    Hubei Keyi Pharmaceutical's ganciclovir is the fourth company to evaluate this variety, and one company has already submitted a supplementary application


    Public information shows that the sales of lansoprazole in 2019 have exceeded 2 billion yuan, and the new sales of thymus for terminal injection in public medical institutions in China in 2018 were 2.


    2 , injections into the protagonist

    2 , injections into the protagonist

    It can be seen from the previous 4 collections that most of them are oral dosage forms


    As we all know, injections have always been a hot spot in the industry


    Compared with before, the rules of injection dosage form have changed a little


    In fact, it is not only national procurement, but also from the procurement policies of various provinces and inter-provincial alliances that injections have become a popular product


    As early as May last year, the consistency evaluation of injections had begun


    3 , leading Pharmaceutical gathered, started a price war

    3 , leading Pharmaceutical gathered, started a price war

    According to GBI data, as of June 8th, in terms of the number of drugs, China Biopharmaceuticals had the most reviewed drugs, with 13 drugs selected.


    In terms of generic drug companies, the fifth batch of 58 nationally sourced products will usher in the competition of 122 over-evaluated companies


    It can be seen from the fifth batch of collections of Hengrui Medicine that 8 varieties have entered, including oxaliplatin injection, cisatracurium benzenesulfonate injection, iodixanol injection, dutaxis Amine soft capsule, docetaxel injection, glycopyrrolate injection, ropivacaine hydrochloride injection and palonosetron hydrochloride injection


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.